US6083903A
(en)
*
|
1994-10-28 |
2000-07-04 |
Leukosite, Inc. |
Boronic ester and acid compounds, synthesis and uses
|
US6838477B2
(en)
*
|
1995-04-12 |
2005-01-04 |
President And Fellows Of Harvard College |
Lactacystin analogs
|
FR2758329B1
(fr)
*
|
1997-01-16 |
1999-02-12 |
Synthelabo |
Derives d'imidazole-4-butane boronique, leur preparation et leur utilisation en therapeutique
|
PT979096E
(pt)
*
|
1997-02-15 |
2003-09-30 |
Millennium Pharm Inc |
Tratamento de enfartes atraves da inibicao de nf-kb
|
US6221888B1
(en)
*
|
1997-05-29 |
2001-04-24 |
Merck & Co., Inc. |
Sulfonamides as cell adhesion inhibitors
|
EP1017398A1
(fr)
*
|
1997-09-25 |
2000-07-12 |
Proscript, Inc. |
INIHIBITEURS DE PROTEASOME, INHIBITEURS DES VOIES DE L'UBIQUITINE OU AGENTS ENTRAVANT L'ACTIVATION DE NF-$g(k)B PAR LES VOIES DE l'UBIQUITINE PROTEASOME POUR TRAITER DES MALADIES INFLAMMATOIRES ET DES MALADIES AUTOIMMUNES
|
ATE357509T1
(de)
*
|
1997-09-29 |
2007-04-15 |
Point Therapeutics Inc |
Stimulierung von hämatopoietischen zellen im vitro
|
US6831057B2
(en)
*
|
1997-10-28 |
2004-12-14 |
The University Of North Carolina At Chapel Hill |
Use of NF-κB inhibition in combination therapy for cancer
|
CA2219867A1
(fr)
*
|
1997-10-31 |
1999-04-30 |
Jiangping Wu |
Utilisation d'inhibiteurs du proteasome dans le traitement du cancer, de l'inflammation, des maladies auto-immunes, du rejet de greffe et du choc septique
|
DE19802450A1
(de)
*
|
1998-01-23 |
1999-07-29 |
Hoechst Marion Roussel De Gmbh |
Ustilipide, Verfahren zu deren Herstellung sowie deren Verwendung
|
US6075150A
(en)
*
|
1998-01-26 |
2000-06-13 |
Cv Therapeutics, Inc. |
α-ketoamide inhibitors of 20S proteasome
|
US6617171B2
(en)
|
1998-02-27 |
2003-09-09 |
The General Hospital Corporation |
Methods for diagnosing and treating autoimmune disease
|
FR2779653B1
(fr)
|
1998-06-11 |
2002-12-20 |
Inst Nat Sante Rech Med |
Utilisation de composes modulateurs du proteasome en therapie
|
US6462019B1
(en)
|
1998-07-10 |
2002-10-08 |
Osteoscreen, Inc. |
Inhibitors of proteasomal activity and production for stimulating bone growth
|
US6838436B1
(en)
*
|
1998-07-10 |
2005-01-04 |
Osteoscreen Inc. |
Inhibitors of proteasomal activity for stimulating bone growth
|
US6902721B1
(en)
|
1998-07-10 |
2005-06-07 |
Osteoscreen, Inc. |
Inhibitors of proteasomal activity for stimulating bone growth
|
US6979697B1
(en)
*
|
1998-08-21 |
2005-12-27 |
Point Therapeutics, Inc. |
Regulation of substrate activity
|
EP0982317A1
(fr)
*
|
1998-08-26 |
2000-03-01 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Inhibiteurs bivalents de protéasome
|
BR9914648A
(pt)
*
|
1998-10-20 |
2001-11-27 |
Millennium Pharm Inc |
Processo para monitorar ação medicamentosa deinibidor de proteasoma
|
US6492333B1
(en)
|
1999-04-09 |
2002-12-10 |
Osteoscreen, Inc. |
Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
|
US6890904B1
(en)
*
|
1999-05-25 |
2005-05-10 |
Point Therapeutics, Inc. |
Anti-tumor agents
|
US6649593B1
(en)
*
|
1999-10-13 |
2003-11-18 |
Tularik Inc. |
Modulators of SREBP processing
|
CA2419238A1
(fr)
*
|
2000-08-16 |
2002-02-21 |
University Of Alberta |
Procedes relatifs a l'elaboration de supports solides conjugues pour les acides boriques, sans recours a la mise sous pression
|
US6919382B2
(en)
|
2000-08-31 |
2005-07-19 |
The Governors Of The University Of Alberta |
Preparation and uses of conjugated solid supports for boronic acids
|
DE50110956D1
(de)
*
|
2000-10-12 |
2006-10-19 |
Viromics Gmbh |
Proteasome inhibitoren zur behandlung von hepatitis-virus infektionen
|
PT1355910E
(pt)
*
|
2001-01-25 |
2011-03-24 |
Us Of America Represented By The Secretary Dept Of Health And Human Services |
Formulação de compostos do ácido borónico
|
US7112588B2
(en)
*
|
2001-05-21 |
2006-09-26 |
Alcon, Inc. |
Use of proteasome inhibitors to treat dry eye disorders
|
DK1392355T3
(da)
|
2001-05-21 |
2007-04-30 |
Alcon Inc |
Anvendelse af proteasominhibitorer tilbehandling af öjentörhedslidelser
|
BR0210112A
(pt)
|
2001-05-30 |
2004-06-08 |
Novartis Ag |
Derivados do ácido 2-{[n-(2-amino-3-(heteroarila ou arila)propionil)-aminoacil]-amino}-alquilborÈnico
|
JPWO2003033507A1
(ja)
*
|
2001-10-12 |
2005-02-03 |
杏林製薬株式会社 |
ベンジルマロン酸誘導体およびそれを含有するプロテアソーム阻害薬
|
JPWO2003033506A1
(ja)
*
|
2001-10-12 |
2005-02-03 |
杏林製薬株式会社 |
アミノボラン酸誘導体およびそれを含有するプロテアソーム阻害薬
|
US7524883B2
(en)
|
2002-01-08 |
2009-04-28 |
Eisai R&D Management Co., Ltd. |
Eponemycin and epoxomicin analogs and uses thereof
|
AU2003218232A1
(en)
*
|
2002-03-12 |
2003-09-29 |
Ariad Pharmaceuticals, Inc. |
Peptide analogues and uses thereof
|
KR20040090981A
(ko)
|
2002-03-13 |
2004-10-27 |
얀센 파마슈티카 엔.브이. |
신규한 히스톤 디아세틸라제 저해제로서의카보닐아미노-유도체
|
AU2003218735B2
(en)
*
|
2002-03-13 |
2009-03-12 |
Janssen Pharmaceutica N.V. |
Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase
|
PL214279B1
(pl)
|
2002-03-13 |
2013-07-31 |
Janssen Pharmaceutica Nv |
Pochodna sulfonyloaminowa, sposób jej wytwarzania i zastosowanie oraz kompozycja farmaceutyczna i sposób jej wytwarzania
|
PL213783B1
(pl)
|
2002-03-13 |
2013-05-31 |
Janssen Pharmaceutica Nv |
Podstawiona pochodna piperydyny lub piperazyny, jej zastosowanie i sposób wytwarzania oraz kompozycja farmaceutyczna
|
DE10391147D2
(de)
*
|
2002-04-05 |
2005-02-17 |
Viromics Gmbh |
Mittel zur Behandlung von Flaviviridae-Infektionen
|
US7514579B2
(en)
*
|
2002-06-13 |
2009-04-07 |
Johns Hopkins University |
Boronic chalcone derivatives and uses thereof
|
JP2006506442A
(ja)
*
|
2002-07-09 |
2006-02-23 |
ポイント セラピューティクス, インコーポレイテッド |
ボロプロリン化合物併用療法
|
ES2282658T3
(es)
*
|
2002-08-14 |
2007-10-16 |
Janssen Pharmaceutica N.V. |
Uso de inhibidores de nf-kappa b para el tratamiento de la mastitis.
|
US20060084592A1
(en)
*
|
2002-09-09 |
2006-04-20 |
Trigen Limited |
Peptide boronic acid inhibitors
|
BR0314450A
(pt)
*
|
2002-09-09 |
2005-07-26 |
Trigen Ltd |
Sais de ácido borÈnico com adição de uma base farmaceuticamente aceitável, formulação farmacêutica, e uso dos referidos sais para preparar uma formulação farmacêutica
|
US20050282757A1
(en)
*
|
2002-09-09 |
2005-12-22 |
Trigen Limited |
Peptide boronic acid compounds useful in anticoagulation
|
US20050176651A1
(en)
*
|
2002-09-09 |
2005-08-11 |
Trigen Limited |
Peptide boronic acids useful in making salts thereof
|
US20050288253A1
(en)
*
|
2002-09-09 |
2005-12-29 |
Trigen Limited |
Boronic acid salts
|
US20050119226A1
(en)
*
|
2003-09-09 |
2005-06-02 |
Trigen Limited |
Methods for synthesizing organoboronic compounds and products thereof
|
EP1542768A1
(fr)
*
|
2002-09-20 |
2005-06-22 |
Alcon, Inc. |
Utilisation d'inhibiteurs de la synthese des cytokines dans le traitement des troubles associes a la keratoconjonctivite seche
|
AU2003298873B2
(en)
|
2002-12-06 |
2011-09-01 |
Millennium Pharmaceuticals, Inc. |
Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy
|
CN100341880C
(zh)
*
|
2003-02-13 |
2007-10-10 |
上海仁虎制药股份有限公司 |
新型硼酸或硼酸酯类化合物、制备方法及在药学上的应用
|
US20070110785A1
(en)
*
|
2003-07-03 |
2007-05-17 |
Eugene Tedeschi |
Medical devices with proteasome inhibitors for the treatment of restenosis
|
US7576206B2
(en)
*
|
2003-08-14 |
2009-08-18 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
US7223745B2
(en)
*
|
2003-08-14 |
2007-05-29 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
BRPI0416243A
(pt)
*
|
2003-11-05 |
2007-01-09 |
Palingen Inc |
método de tratamento de um paciente humano que sofre de uma condição que inclui uma hiper-proliferação de células b; formulação farmacêutica para injeção parenteral; kit para o tratamento de um paciente que sofre de uma condição que inclui uma hiper-proliferação de células b; e método para purgar a medula óssea de um paciente que sofre de cáncer linfóide de células b malignas antes do reimplante da medula óssea no paciente após a terapia mieloablativa
|
US20060052390A1
(en)
*
|
2003-12-24 |
2006-03-09 |
Scios, Inc. |
Treatment of multiple myeloma by p38 MAP kinase and proteasome inhibition
|
KR20130016435A
(ko)
*
|
2004-02-23 |
2013-02-14 |
트러스티즈 오브 터프츠 칼리지 |
디펩티딜펩티다아제 ⅳ의 억제제
|
GB0405272D0
(en)
*
|
2004-03-09 |
2004-04-21 |
Trigen Ltd |
Compounds
|
US7371875B2
(en)
*
|
2004-03-12 |
2008-05-13 |
Miikana Therapeutics, Inc. |
Cytotoxic agents and methods of use
|
RS65253B1
(sr)
|
2004-03-30 |
2024-03-29 |
Millennium Pharm Inc |
Sinteza jedinjenja estra organoborne kiseline i organoborne kiseline
|
AU2016202747B2
(en)
*
|
2004-03-30 |
2017-11-23 |
Millennium Pharmaceuticals, Inc. |
Synthesis of boronic ester and acid compounds
|
US8198270B2
(en)
|
2004-04-15 |
2012-06-12 |
Onyx Therapeutics, Inc. |
Compounds for proteasome enzyme inhibition
|
CN102174076A
(zh)
|
2004-04-15 |
2011-09-07 |
普罗特奥里克斯公司 |
用于抑制蛋白酶体酶的化合物
|
RU2384585C2
(ru)
|
2004-05-10 |
2010-03-20 |
Протеоликс, Инк. |
Соединения для ингибирования ферментов
|
CA2571421A1
(fr)
|
2004-06-24 |
2006-01-05 |
Nicholas Valiante |
Composes utilises pour l'immunopotentialisation
|
JP2008507541A
(ja)
|
2004-07-23 |
2008-03-13 |
ロイヤルティ,スーザン・マリー |
ペプチダーゼ阻害剤
|
AU2005266312C1
(en)
|
2004-07-28 |
2011-06-16 |
Janssen Pharmaceutica N.V. |
Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
|
CA2584515A1
(fr)
|
2004-10-20 |
2006-04-27 |
Proteolix, Inc. |
Composes pour inhibition d'enzymes
|
TW200618820A
(en)
*
|
2004-11-05 |
2006-06-16 |
Alza Corp |
Liposome formulations of boronic acid compounds
|
ES2551502T3
(es)
|
2004-11-05 |
2015-11-19 |
Igm Biosciences, Inc. |
Formación de heridas en la membrana celular inducida por anticuerpos
|
US8017395B2
(en)
|
2004-12-17 |
2011-09-13 |
Lifescan, Inc. |
Seeding cells on porous supports
|
US20070098685A1
(en)
*
|
2005-01-19 |
2007-05-03 |
Brand Stephen J |
Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist
|
ES2552338T3
(es)
|
2005-01-21 |
2015-11-27 |
Astex Therapeutics Limited |
Compuestos farmacéuticos
|
CA2595749A1
(fr)
*
|
2005-01-27 |
2006-08-03 |
Research Development Foundation |
Therapie de combinaison avec des composes triterpenoides et des inhibiteurs de proteasome
|
US7468383B2
(en)
*
|
2005-02-11 |
2008-12-23 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
KR101337045B1
(ko)
|
2005-02-16 |
2013-12-05 |
아나코르 파마슈티칼스 인코포레이티드 |
보론함유 소분자
|
EP1863513A2
(fr)
*
|
2005-03-11 |
2007-12-12 |
The University of North Carolina at Chapel Hill |
Inhibiteurs puissants et spécifiques d'immunoprotéasomes
|
KR20080007642A
(ko)
*
|
2005-04-29 |
2008-01-22 |
코산 바이오사이언시즈, 인코포레이티드 |
프로테아좀 억제제와 함께 17-aag 또는 17-ag 또는 둘중 하나의 전구약물을 사용하여 다발성 골수종을 치료하는방법
|
CA2605272C
(fr)
|
2005-05-18 |
2013-12-10 |
Janssen Pharmaceutica N.V. |
Derives substitues d'aminopropenyl-piperidine ou de morpholine utilises en tant qu'inhibiteurs de l'histone-desacetylase
|
AU2006202209B2
(en)
*
|
2005-05-27 |
2011-04-14 |
Lifescan, Inc. |
Amniotic fluid derived cells
|
US9074189B2
(en)
*
|
2005-06-08 |
2015-07-07 |
Janssen Biotech, Inc. |
Cellular therapy for ocular degeneration
|
US20090017006A1
(en)
*
|
2005-07-06 |
2009-01-15 |
Biodevelops Pharma Entwicklung Gmbh |
Use of a compound for enhancing the expression of membrane proteins on the cell surface
|
EP1752467A1
(fr)
|
2005-08-10 |
2007-02-14 |
4Sc Ag |
Inhibiteurs de la proliferation de cellules cancereuses, de cellules t, et de keratinocytes
|
US7531517B2
(en)
|
2005-08-10 |
2009-05-12 |
4Sc Ag |
Inhibitors of cancer cell, T-cell and keratinocyte proliferation
|
US20070059382A1
(en)
*
|
2005-09-09 |
2007-03-15 |
Board Of Regents, Univ. And Comm. College System Of Nevada... |
Medical treatment of breast cancer with boric acid materials
|
PT2623113T
(pt)
|
2005-11-09 |
2017-07-14 |
Onyx Therapeutics Inc |
Compostos para inibição de enzimas
|
US20090221488A1
(en)
*
|
2005-12-08 |
2009-09-03 |
Wood Kenneth W |
Certain Compositions and Methods of Treatment
|
EP1976536A4
(fr)
|
2005-12-30 |
2011-03-02 |
Anacor Pharmaceuticals Inc |
Petites molecules contenant du bore
|
ATE432272T1
(de)
*
|
2006-01-19 |
2009-06-15 |
Janssen Pharmaceutica Nv |
Aminophenylderivate als neue inhibitoren von histondeacetylase
|
WO2007082882A1
(fr)
*
|
2006-01-19 |
2007-07-26 |
Janssen Pharmaceutica N.V. |
Dérivé d'indolyl-alkyl-amino substitués en tant qu'inhibiteurs d'histone désacétylase
|
AU2007206944B2
(en)
*
|
2006-01-19 |
2012-08-23 |
Janssen Pharmaceutica N.V. |
Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
|
CA2630717C
(fr)
*
|
2006-01-19 |
2015-02-24 |
Janssen Pharmaceutica N.V. |
Derives de pyridine et de pyrimidine en tant qu'inhibiteurs d'histone desacetylase
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
PE20070978A1
(es)
*
|
2006-02-14 |
2007-11-15 |
Novartis Ag |
COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
|
WO2007095638A2
(fr)
*
|
2006-02-16 |
2007-08-23 |
Anacor Pharmaceuticals, Inc. |
Petites molecules contenant du bore en tant qu'agents anti-inflammatoires
|
AR060358A1
(es)
*
|
2006-04-06 |
2008-06-11 |
Novartis Vaccines & Diagnostic |
Quinazolinas para la inhibicion de pdk 1
|
US8741643B2
(en)
|
2006-04-28 |
2014-06-03 |
Lifescan, Inc. |
Differentiation of pluripotent stem cells to definitive endoderm lineage
|
DE102006026464A1
(de)
|
2006-06-01 |
2007-12-06 |
Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma |
Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
|
US7910108B2
(en)
*
|
2006-06-05 |
2011-03-22 |
Incyte Corporation |
Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
|
JP5226679B2
(ja)
|
2006-06-19 |
2013-07-03 |
プロテオリックス, インコーポレイテッド |
酵素阻害のための化合物
|
JP5185274B2
(ja)
*
|
2006-09-15 |
2013-04-17 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
プロテアソームインヒビターと組み合わせてクラスiおよびクラスiibヒストンデアセチラーゼに対する組み合わせ活性を持つヒストンデアセチラーゼインヒビター
|
RU2456990C2
(ru)
*
|
2006-09-15 |
2012-07-27 |
Янссен Фармацевтика Нв |
Комбинации специфичных ингибиторов гистоновых деацетилаз класса i с ингибиторами протеасом
|
JP5528806B2
(ja)
|
2006-10-12 |
2014-06-25 |
アステックス、セラピューティックス、リミテッド |
複合薬剤
|
WO2008044045A1
(fr)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Combinaisons pharmaceutiques
|
CA2606634A1
(fr)
*
|
2006-12-08 |
2008-06-08 |
Centenary Institute Of Cancer Medicine And Cell Biology |
Essai biologique repondant aux effets des inhibiteurs du proteasome
|
JO3396B1
(ar)
|
2007-06-20 |
2019-10-20 |
Anacor Pharmaceuticals Inc |
جزيئات صغيرة تحتوي على البورون
|
US9080145B2
(en)
*
|
2007-07-01 |
2015-07-14 |
Lifescan Corporation |
Single pluripotent stem cell culture
|
DK2185693T3
(da)
|
2007-07-31 |
2019-09-23 |
Lifescan Inc |
Differentiering af humane embryoniske stamceller
|
MX2009012558A
(es)
|
2007-08-03 |
2010-04-21 |
Biomarin Iga Ltd |
Combinaciones de farmacos para el tratamiento de distrofia muscular de duchenne.
|
GB0715087D0
(en)
|
2007-08-03 |
2007-09-12 |
Summit Corp Plc |
Drug combinations for the treatment of duchenne muscular dystrophy
|
EA034601B1
(ru)
*
|
2007-08-06 |
2020-02-25 |
Милленниум Фармасьютикалз, Инк. |
Способ получения бороновых кислот
|
AU2016253697A1
(en)
*
|
2007-08-06 |
2016-11-24 |
Millennium Pharmaceuticals, Inc. |
Proteasome inhibitors
|
US7442830B1
(en)
|
2007-08-06 |
2008-10-28 |
Millenium Pharmaceuticals, Inc. |
Proteasome inhibitors
|
KR20160040735A
(ko)
*
|
2007-08-06 |
2016-04-14 |
밀레니엄 파머슈티컬스 인코퍼레이티드 |
프로테아좀 억제제
|
MX2010002836A
(es)
*
|
2007-09-12 |
2010-03-31 |
Reddys Lab Ltd Dr |
Bortezomib y proceso para la produccion del mismo.
|
US20090076031A1
(en)
*
|
2007-09-17 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched bortezomib
|
HUE029665T2
(en)
|
2007-10-04 |
2017-03-28 |
Onyx Therapeutics Inc |
Synthesis of crystalline peptide epoxy ketone protease inhibitors and amino acid keto epoxides \ t
|
US7838673B2
(en)
*
|
2007-10-16 |
2010-11-23 |
Millennium Pharmaceuticals, Inc. |
Proteasome inhibitors
|
US20090110688A1
(en)
*
|
2007-10-24 |
2009-04-30 |
Georg Fertig |
Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
|
KR101592182B1
(ko)
*
|
2007-11-27 |
2016-02-05 |
라이프스캔, 인코포레이티드 |
인간 배아 줄기 세포의 분화
|
CN101220048B
(zh)
*
|
2007-12-14 |
2012-08-15 |
江苏先声药物研究有限公司 |
ZnCl2催化下的蒎烷二醇酯的制备方法
|
KR20100093129A
(ko)
|
2007-12-20 |
2010-08-24 |
노파르티스 아게 |
Pi 3 키나제 억제제로서 사용되는 티아졸 유도체
|
RU2551772C2
(ru)
|
2008-02-21 |
2015-05-27 |
Сентокор Орто Байотек Инк. |
Способы, поверхностно-модифицированные носители и композиции для иммобилизации, культивирования и открепления клеток
|
US8039450B2
(en)
|
2008-03-06 |
2011-10-18 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as anti-inflammatory agents
|
WO2009140309A2
(fr)
*
|
2008-05-12 |
2009-11-19 |
Anacor Pharmaceuticals, Inc. |
Petites molécules contenant du bore
|
EA027346B1
(ru)
|
2008-06-17 |
2017-07-31 |
Милленниум Фармасьютикалз, Инк. |
Соединения боронатного эфира и его фармацевтические составы
|
EP2310492B1
(fr)
|
2008-06-30 |
2015-07-22 |
Janssen Biotech, Inc. |
Différenciation de cellules souches pluripotentes
|
CN101638414B
(zh)
*
|
2008-07-30 |
2014-01-08 |
江苏先声药物研究有限公司 |
肽硼酸及其酯类化合物、制备方法及其用途
|
US20100028307A1
(en)
*
|
2008-07-31 |
2010-02-04 |
O'neil John J |
Pluripotent stem cell differentiation
|
US8461336B2
(en)
|
2008-09-04 |
2013-06-11 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules
|
WO2010027975A1
(fr)
*
|
2008-09-04 |
2010-03-11 |
Anacor Pharmaceuticals, Inc. |
Petites molécules contenant du bore
|
AR075090A1
(es)
|
2008-09-29 |
2011-03-09 |
Millennium Pharm Inc |
Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
|
US9493489B2
(en)
*
|
2008-10-15 |
2016-11-15 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as anti-protozoal agents
|
EP2796134B1
(fr)
*
|
2008-10-21 |
2016-12-07 |
Onyx Therapeutics, Inc. |
Combinaison du peptide époxycétone inhibiteur du protéasome carfilzomib avec le melphalan pour utilisation dans le traitement du myélome multiple
|
EP2350265B1
(fr)
|
2008-10-31 |
2019-04-17 |
Janssen Biotech, Inc. |
Différenciation de cellules souches embryonnaires humaines en la lignée endocrine pancréatique
|
CA2742268C
(fr)
|
2008-10-31 |
2020-02-18 |
Centocor Ortho Biotech Inc. |
Differenciation de cellules souches embryonnaires humaines en la lignee endocrine pancreatique
|
US20100124781A1
(en)
|
2008-11-20 |
2010-05-20 |
Shelley Nelson |
Pluripotent Stem Cell Culture on Micro-Carriers
|
RU2547925C2
(ru)
*
|
2008-11-20 |
2015-04-10 |
Сентокор Орто Байотек Инк. |
Способы и композиции для закрепления и культивирования клеток на плоских носителях
|
CN101747354B
(zh)
*
|
2008-12-04 |
2014-08-13 |
江苏先声药物研究有限公司 |
一类β氨基酸组成的二肽硼酸及其酯类化合物、制备方法及其用途
|
CN102256494A
(zh)
*
|
2008-12-17 |
2011-11-23 |
阿纳科制药公司 |
(s)-3-氨甲基-7-(3-羟基-丙氧基)-3h-苯并[c][1,2]氧杂硼杂环戊-1-醇的多晶型物
|
EA201170921A1
(ru)
*
|
2009-01-09 |
2012-01-30 |
Сан Фарма Адвансед Ресёрч Компани Лимитед |
Фармацевтическая композиция
|
WO2010096574A1
(fr)
|
2009-02-20 |
2010-08-26 |
Lisanti Michael P |
Procédé de diagnostic ou de pronostic d'un néoplasme comprenant la détermination du taux d'expression d'une protéine dans des cellules stromales adjacentes au néoplasme
|
CA2753285A1
(fr)
|
2009-03-12 |
2010-09-16 |
Genentech, Inc. |
Combinaisons de composes inhibiteurs de phosphoinositide 3-kinase et d'agents chimiotherapeutiques pour le traitement de tumeurs malignes hematopoietiques
|
WO2010106135A1
(fr)
|
2009-03-20 |
2010-09-23 |
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. |
Utilisation combinée pour le traitement d'un carcinome ovarien
|
TWI504598B
(zh)
|
2009-03-20 |
2015-10-21 |
Onyx Therapeutics Inc |
結晶性三肽環氧酮蛋白酶抑制劑
|
DK2411535T3
(en)
|
2009-03-24 |
2015-07-13 |
Janssen Pharmaceutica Nv |
BIOMAR RUNNING FOR ASSESSMENT OF PERIPHERAL NEUROPATHY RESPONSE TO TREATMENT WITH a proteasome inhibitor
|
WO2010114770A1
(fr)
*
|
2009-03-30 |
2010-10-07 |
Cerulean Pharma Inc. |
Conjugués polymère-agent, particules, compositions et procédés d'utilisation apparentés
|
WO2010114768A1
(fr)
*
|
2009-03-30 |
2010-10-07 |
Cerulean Pharma Inc. |
Conjugués polymère-épothilone, particules, compositions et procédés d'utilisation apparentés
|
EA201171195A8
(ru)
*
|
2009-03-30 |
2014-08-29 |
Серулин Фарма Инк. |
Конъюгаты, частицы, композиции "полимер-агент" и способы их применения
|
AU2009347159B2
(en)
*
|
2009-05-27 |
2015-09-03 |
Cephalon, Inc. |
Combination therapy for the treatment of multiple myeloma
|
EP2270019A1
(fr)
|
2009-06-19 |
2011-01-05 |
LEK Pharmaceuticals d.d. |
Nouvelle voie de synthèse pour la préparation d'esters boronique alpha-aminé
|
CN101928329B
(zh)
|
2009-06-19 |
2013-07-17 |
北京大学 |
三肽硼酸(酯)类化合物、其制备方法和应用
|
JP2012530116A
(ja)
|
2009-06-19 |
2012-11-29 |
レツク・フアーマシユーテイカルズ・デー・デー |
脱ハロゲン化なしにハロゲノアルケンを水素化する方法
|
EP2280016A1
(fr)
|
2009-07-27 |
2011-02-02 |
LEK Pharmaceuticals d.d. |
Nouvelle voie de synthèse pour la préparation d'esters boroniques aminés via des Alk-1-ynes substitués
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
DE102009027754A1
(de)
|
2009-07-15 |
2011-05-05 |
Schubert, Ulrich, Dr. |
Verfahren zur Hemmung der Reifung von dendritischen Zellen
|
AU2010276438B2
(en)
|
2009-07-20 |
2015-06-11 |
Janssen Biotech Inc. |
Differentiation of human embryonic stem cells
|
PL2456858T3
(pl)
*
|
2009-07-20 |
2019-01-31 |
Janssen Biotech, Inc |
Różnicowanie ludzkich embrionalnych komórek macierzystych
|
BR112012001564A2
(pt)
|
2009-07-20 |
2015-09-01 |
Janssen Biotech Inc |
Diferenciação de células tronco embrionárias humanas.
|
AU2010281439A1
(en)
*
|
2009-07-28 |
2012-03-15 |
Anacor Pharmaceuticals, Inc. |
Trisubstituted boron-containing molecules
|
WO2011019618A1
(fr)
*
|
2009-08-14 |
2011-02-17 |
Anacor Pharmaceuticals, Inc. |
Petites molécules contenant du bore et utilisables en tant qu'agents antiprotozoaires
|
US20120149663A1
(en)
|
2009-08-18 |
2012-06-14 |
Georgetown University |
Boronic acid compositions and methods related to cancer
|
US20110207701A1
(en)
*
|
2009-08-19 |
2011-08-25 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as antiprotozoal agents
|
ES2557316T3
(es)
|
2009-09-08 |
2016-01-25 |
F. Hoffmann-La Roche Ag |
Compuestos de piridín-3-il-carboxamida 4-sustituidos y métodos de utilización
|
US20110124597A1
(en)
*
|
2009-09-25 |
2011-05-26 |
Anacor Pharmaceuticals, Inc. |
Boron containing small molecules
|
EP2305285A1
(fr)
|
2009-09-29 |
2011-04-06 |
Julius-Maximilians-Universität Würzburg |
Supports et procédés pour traiter les conditions ischémiques
|
DK2519231T3
(en)
*
|
2009-10-01 |
2017-06-26 |
Janssen Pharmaceutica Nv |
Proteasome inhibitors for the treatment of cancer
|
WO2011049971A1
(fr)
|
2009-10-20 |
2011-04-28 |
Anacor Pharmaceuticals, Inc. |
Petites molécules contenant du bore comme agents antiprotozoaires
|
WO2011060196A1
(fr)
*
|
2009-11-11 |
2011-05-19 |
Anacor Pharmaceuticals, Inc. |
Petites molecules contenant du bore
|
US8853147B2
(en)
|
2009-11-13 |
2014-10-07 |
Onyx Therapeutics, Inc. |
Use of peptide epoxyketones for metastasis suppression
|
EP2516449A1
(fr)
|
2009-12-22 |
2012-10-31 |
Cephalon, Inc. |
Inhibiteurs du protéasome et leurs procédés de préparation, d'épuration et d'utilisation
|
RU2610176C2
(ru)
|
2009-12-23 |
2017-02-08 |
Янссен Байотек, Инк. |
Дифференцировка человеческих эмбриональных стволовых клеток
|
CN102712902B
(zh)
|
2009-12-23 |
2019-01-08 |
詹森生物科技公司 |
人胚胎干细胞的分化
|
WO2011090940A1
(fr)
|
2010-01-19 |
2011-07-28 |
Cerulean Pharma Inc. |
Polymères à base de cyclodextrine pour administration thérapeutique
|
US8716478B2
(en)
|
2010-01-27 |
2014-05-06 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules
|
WO2011109279A2
(fr)
|
2010-03-01 |
2011-09-09 |
Centocor Ortho Biotech Inc. |
Procédés de purification de cellules issues de cellules souches pluripotentes
|
MA34133B1
(fr)
|
2010-03-01 |
2013-04-03 |
Onyx Therapeutics Inc |
Composes pour inhibiteurs de l'immunoproteasome
|
US9061037B2
(en)
*
|
2010-03-18 |
2015-06-23 |
Innopharma, Inc. |
Stable bortezomib formulations
|
US8263578B2
(en)
|
2010-03-18 |
2012-09-11 |
Innopharma, Inc. |
Stable bortezomib formulations
|
US8623911B2
(en)
|
2010-03-19 |
2014-01-07 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as anti-protozoal agent
|
CA2793959C
(fr)
|
2010-03-25 |
2019-06-04 |
Oregon Health & Science University |
Glycoproteines du cmv et vecteurs recombines
|
AU2013204868B2
(en)
*
|
2010-03-31 |
2016-10-13 |
Millennium Pharmaceuticals, Inc. |
Derivatives of 1-amino-2-cyclopropylethylboronic acid
|
CN107266485A
(zh)
*
|
2010-03-31 |
2017-10-20 |
米伦纽姆医药公司 |
1‑氨基‑2‑环丙基乙硼酸衍生物
|
RU2012147246A
(ru)
|
2010-04-07 |
2014-05-20 |
Оникс Терапьютикс, Инк. |
Кристаллический пептидный эпоксикетонный ингебитор иммунопротеасомы
|
CN101812026B
(zh)
*
|
2010-04-12 |
2013-08-28 |
亚邦医药股份有限公司 |
一种硼替佐米的合成方法
|
WO2011133479A2
(fr)
|
2010-04-19 |
2011-10-27 |
Niiki Pharma Inc. |
Polythérapie avec un inhibiteur du protéasome et un complexe de gallium
|
WO2011139379A2
(fr)
|
2010-05-06 |
2011-11-10 |
Duke University |
Méthode de traitement de patients suivant une thérapie de remplacement de protéine, une thérapie de remplacement de gène ou d'autres modalités thérapeutiques
|
AU2011250912A1
(en)
|
2010-05-12 |
2012-11-22 |
Janssen Biotech, Inc. |
Differentiation of human embryonic stem cells
|
CA2927832C
(fr)
|
2010-05-18 |
2021-03-23 |
Cerulean Pharma Inc. |
Conjugues d'agent therapeutique polymere renfermant de la cyclodextrine et leur utilisation
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
CA2809300A1
(fr)
|
2010-08-31 |
2012-03-08 |
Janssen Biotech, Inc. |
Differenciation de cellules souches embryonnaires humaines
|
US9528090B2
(en)
|
2010-08-31 |
2016-12-27 |
Janssen Biotech, Inc. |
Differentiation of human embryonic stem cells
|
MX348537B
(es)
|
2010-08-31 |
2017-06-07 |
Janssen Biotech Inc |
Diferencia de celulas madre pluripotentes.
|
PL3251678T3
(pl)
|
2010-09-07 |
2022-01-10 |
Anacor Pharmaceuticals, Inc. |
Pochodne benzoksaborolu do leczenia zakażeń bakteryjnych
|
US9126997B1
(en)
|
2010-09-07 |
2015-09-08 |
Northwestern University |
Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
|
WO2012047845A1
(fr)
|
2010-10-05 |
2012-04-12 |
App Pharmaceuticals |
Formulations de bortézomib stabilisées par de l'acide borique
|
US8884009B2
(en)
|
2010-10-14 |
2014-11-11 |
Synthon Bv |
Process for making bortezomib and intermediates for the process
|
JP5963777B2
(ja)
|
2011-01-31 |
2016-08-03 |
ノバルティス アーゲー |
新規ヘテロ環誘導体
|
TW201309303A
(zh)
*
|
2011-03-03 |
2013-03-01 |
Cephalon Inc |
用於治療狼瘡的蛋白酶體抑制劑
|
US9272014B2
(en)
|
2011-03-29 |
2016-03-01 |
Texas Tech University System |
Galectin-3C combination therapy for human cancer
|
KR101869125B1
(ko)
|
2011-03-31 |
2018-06-19 |
나노캬리아 가부시키가이샤 |
보론산 화합물을 함유한 블록 공중합체를 포함하는 의약 조성물
|
WO2012170765A2
(fr)
|
2011-06-10 |
2012-12-13 |
Oregon Health & Science University |
Glycoprotéines de cmv et vecteurs recombinants cmv
|
EP2723751A1
(fr)
*
|
2011-06-22 |
2014-04-30 |
Cephalon, Inc. |
Inhibiteurs du protéasome et leurs méthodes de préparation, de purification et d'utilisation
|
US8481655B2
(en)
|
2011-07-27 |
2013-07-09 |
Wacker Chemical Corporation |
Copper complexes of amino-functional organosilicon compounds and their use
|
US9322066B2
(en)
|
2011-08-11 |
2016-04-26 |
Janssen Pharmaceutica Nv |
Predictors for cancer treatment
|
WO2013021032A1
(fr)
|
2011-08-11 |
2013-02-14 |
Janssen Pharmaceutica Nv |
Inhibiteurs d'histone désacétylase en combinaison avec des inhibiteurs du protéasome et la dexaméthasone
|
RS55462B1
(sr)
|
2011-08-19 |
2017-04-28 |
Glaxo Group Ltd |
Jedinjenja benzofurana za tretiranje infekcija sa virusom hepatitisa c
|
EP2753334B1
(fr)
|
2011-08-30 |
2022-10-19 |
Trustees Of Tufts College |
Inhibiteurs de protéasome activés par fap utilisés pour traiter les tumeurs solides
|
CA2789539A1
(fr)
|
2011-09-12 |
2013-03-12 |
International Aids Vaccine Initiative |
Immunoselection de virus de la stomatite vesiculeuse recombinant exprimant des proteines hiv-1 en neutralisant largement les anticorps
|
US9402894B2
(en)
|
2011-10-27 |
2016-08-02 |
International Aids Vaccine Initiative |
Viral particles derived from an enveloped virus
|
CN104039790B
(zh)
|
2011-10-28 |
2016-04-13 |
诺华股份有限公司 |
嘌呤衍生物及它们在治疗疾病中的应用
|
EP2775844B1
(fr)
|
2011-10-28 |
2019-12-11 |
Millennium Pharmaceuticals, Inc. |
Biomarqueurs de réponse aux inhibiteurs de nae
|
WO2013071142A1
(fr)
|
2011-11-11 |
2013-05-16 |
Millennium Pharmaceuticals, Inc. |
Biomarqueurs de la sensibilité à des inhibiteurs du protéasome
|
WO2013071163A2
(fr)
|
2011-11-11 |
2013-05-16 |
Millennium Pharamaceuticals, Inc. |
Biomarqueurs de la sensibilité vis-à-vis d'inhibiteurs du protéasome
|
IN2014CN03580A
(fr)
|
2011-11-17 |
2015-10-09 |
Univ Tokyo |
|
CA2860107C
(fr)
|
2011-12-22 |
2021-06-01 |
Janssen Biotech, Inc. |
Differenciation de cellules souches embryonnaires humaines en cellules positives pour l'insuline hormonales individuelles
|
US9732101B2
(en)
|
2012-01-18 |
2017-08-15 |
Wisconsin Alumni Research Foundation |
Bioreversible boronates for delivery of molecules into cells
|
US9234048B2
(en)
|
2012-01-18 |
2016-01-12 |
Wisconsin Alumni Research Foundation |
Boronate-mediated delivery of molecules into cells
|
JP6215235B2
(ja)
|
2012-01-24 |
2017-10-18 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
癌の治療方法
|
WO2013112881A1
(fr)
|
2012-01-27 |
2013-08-01 |
Thomas Jefferson University |
Procédés pronostique et thérapeutique liés à l'inhibiteur de la protéine mct
|
JP6335796B2
(ja)
|
2012-02-08 |
2018-06-06 |
アイジーエム バイオサイエンシズ インク.Igm Biosciences Inc. |
Cdim結合タンパク質及びその使用
|
AU2013227219A1
(en)
|
2012-03-02 |
2014-10-23 |
Dr. Reddy's Laboratories Limited |
Pharmaceutical compositions comprising boronic acid compounds
|
RU2664467C2
(ru)
|
2012-03-07 |
2018-08-17 |
Янссен Байотек, Инк. |
Среда определенного состава для размножения и обновления плюрипотентных стволовых клеток
|
CA2784240C
(fr)
|
2012-03-27 |
2014-07-08 |
Innopharma, Inc. |
Formulations stables a base de bortezomib
|
BR112014028420A2
(pt)
|
2012-05-16 |
2017-09-19 |
Novartis Ag |
regime de dosagem para um inibidor de quinase pi-3
|
RU2018108850A
(ru)
|
2012-06-08 |
2019-02-26 |
Янссен Байотек, Инк. |
Дифференцировка эмбриональных стволовых клеток человека в панкреатические эндокринные клетки
|
ES2631608T3
(es)
|
2012-06-27 |
2017-09-01 |
International Aids Vaccine Initiative |
Variante de la glicoproteína Env del VIH-1
|
UY34897A
(es)
|
2012-07-09 |
2014-01-31 |
Onyx Therapeutics Inc |
Profarmacos de inhibidores peptidicos de expoxi cetona proteasa
|
JP2013006855A
(ja)
*
|
2012-09-03 |
2013-01-10 |
Millennium Pharmaceuticals Inc |
プロテアソーム阻害剤
|
KR20150067175A
(ko)
*
|
2012-09-11 |
2015-06-17 |
시플라 리미티드 |
보르테조밉을 제조하기 위한 방법
|
CN104822844B
(zh)
|
2012-10-01 |
2019-05-07 |
米伦纽姆医药公司 |
预测对抑制剂的反应的生物标记物和方法以及其用途
|
WO2014072985A1
(fr)
|
2012-11-06 |
2014-05-15 |
Natco Pharma Limited |
Nouveaux dérivés d'acide boronique an tant qu'agents anticancéreux
|
AU2013346322B2
(en)
|
2012-11-16 |
2016-11-10 |
Shilpa Medicare Limited |
Crystalline Bortezomib process
|
WO2014097306A1
(fr)
|
2012-12-21 |
2014-06-26 |
Natco Pharma Limited |
Forme polymorphe stable et pure du bortézomib
|
KR102036780B1
(ko)
|
2012-12-31 |
2019-10-25 |
얀센 바이오테크 인코포레이티드 |
Hb9 조절제를 사용하는 인간 배아 줄기세포의 췌장 내분비 세포로의 분화
|
RU2768963C2
(ru)
|
2012-12-31 |
2022-03-25 |
Янссен Байотек, Инк. |
Культивация эмбриональных стволовых клеток человека в воздушно-жидкостной зоне взаимодействия с целью их дифференцировки в панкреатические эндокринные клетки
|
US10377989B2
(en)
|
2012-12-31 |
2019-08-13 |
Janssen Biotech, Inc. |
Methods for suspension cultures of human pluripotent stem cells
|
US10370644B2
(en)
|
2012-12-31 |
2019-08-06 |
Janssen Biotech, Inc. |
Method for making human pluripotent suspension cultures and cells derived therefrom
|
RU2737434C2
(ru)
|
2013-03-13 |
2020-11-30 |
Форма Терапьютикс, Инк. |
Новые соединения и композиции для ингибирования fasn
|
IN2013MU01431A
(fr)
|
2013-04-16 |
2015-06-26 |
Cipla Ltd |
|
WO2014172627A1
(fr)
|
2013-04-19 |
2014-10-23 |
Thomas Jefferson University |
Methodes associees a la caveoline-1 pour le traitement d'un glioblastome par temozolomide
|
US9603775B2
(en)
|
2013-04-24 |
2017-03-28 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US10478445B2
(en)
|
2013-07-03 |
2019-11-19 |
Georgetown University |
Boronic acid derivatives of resveratrol for activating deacetylase enzymes
|
EP2848937A1
(fr)
|
2013-09-05 |
2015-03-18 |
International Aids Vaccine Initiative |
Procédés d'identification de nouveaux immunogènes du VIH-1
|
US20160250238A1
(en)
|
2013-10-03 |
2016-09-01 |
Millennium Pharmaceuticals, Inc. |
Method for the Prophylaxis or Treatment of Systemic Lupus Erythematosus and/or Lupus Nephritis
|
US10058604B2
(en)
|
2013-10-07 |
2018-08-28 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
CN104586776B
(zh)
*
|
2013-10-30 |
2017-05-17 |
扬子江药业集团上海海尼药业有限公司 |
以硼替佐米为活性成分的制剂及其制备方法
|
JP6468562B2
(ja)
*
|
2013-11-21 |
2019-02-13 |
国立大学法人北海道大学 |
プロテアソーム阻害性化合物
|
US10191033B2
(en)
|
2013-12-05 |
2019-01-29 |
The Broad Institute, Inc. |
Biomarkers for detecting pre-cachexia or cachexia and methods of treatment thereof
|
JP2016539149A
(ja)
|
2013-12-06 |
2016-12-15 |
ノバルティス アーゲー |
アルファ−アイソフォーム選択的ホスファチジルイノシトール3−キナーゼ阻害剤の投薬レジメン
|
WO2015117136A1
(fr)
|
2014-02-03 |
2015-08-06 |
Ohio State Innovation Foundation |
Esters d'acide boronique et leurs formulations pharmaceutiques
|
EP2910557A1
(fr)
*
|
2014-02-20 |
2015-08-26 |
Ikerchem, S.L. |
Pyrrolidines tétrasubstitués énantiopures en tant qu'échafaudages pour inhibiteurs de protéasome et ses applications médicinales
|
US10993960B1
(en)
|
2014-05-08 |
2021-05-04 |
Kawasaki Institute Of Industrial Promotion |
Pharmaceutical composition
|
SG10201810739VA
(en)
|
2014-05-16 |
2019-01-30 |
Janssen Biotech Inc |
Use of small molecules to enhance mafa expression in pancreatic endocrine cells
|
NZ725948A
(en)
|
2014-05-20 |
2024-01-26 |
Takeda Pharmaceuticals Co |
Boron-containing proteasome inhibitors for use after primary cancer therapy
|
EP3177292B1
(fr)
|
2014-08-07 |
2020-11-25 |
Mayo Foundation for Medical Education and Research |
Composés et méthodes de traitement du cancer
|
US10253049B2
(en)
*
|
2014-10-01 |
2019-04-09 |
Merck Patent Gmbh |
Boronic acid derivatives
|
WO2016110870A1
(fr)
|
2015-01-07 |
2016-07-14 |
Emcure Pharmaceuticals Limited |
Composition pharmaceutique de bortézomid
|
MA41505A
(fr)
|
2015-02-11 |
2017-12-19 |
Millennium Pharm Inc |
Nouvelle forme cristalline d'un inhibiteur de protéasome
|
US20180243217A1
(en)
|
2015-03-17 |
2018-08-30 |
Leon-Nanodrugs Gmbh |
Nanoparticles comprising a stabilized boronic acid compound
|
EP3069730A3
(fr)
|
2015-03-20 |
2017-03-15 |
International Aids Vaccine Initiative |
Trimères de glycoprotéines de l'enveloppe du vih-1 soluble
|
US9931394B2
(en)
|
2015-03-23 |
2018-04-03 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
WO2016184793A1
(fr)
|
2015-05-15 |
2016-11-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Méthodes de traitement de patients souffrant d'un adénocarcinome rénal métastatique résistant aux inhibiteurs du vegfr
|
WO2016205790A2
(fr)
|
2015-06-19 |
2016-12-22 |
Hanlin Scientific, Inc. |
Composés spécifiques chiraux à base de bore et leur utilisation dans le traitement du cancer ou de l'amyloïdose
|
EP3120836A1
(fr)
|
2015-07-22 |
2017-01-25 |
Stada Arzneimittel Ag |
Solution de bortezomib prêts à l'emploi
|
EP3120837A1
(fr)
|
2015-07-22 |
2017-01-25 |
Stada Arzneimittel Ag |
Solution de bortezomib prêts à l'emploi
|
CN106478700B
(zh)
*
|
2015-08-26 |
2020-12-29 |
杭州雷索药业有限公司 |
硼基取代的苯胺类蛋白激酶抑制剂
|
CN106588965A
(zh)
*
|
2015-10-15 |
2017-04-26 |
北京大学 |
脲拟肽硼酸化合物及其药物组合物、制备方法和用途
|
AU2016347881A1
(en)
|
2015-11-02 |
2018-05-10 |
Novartis Ag |
Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
|
EP3389715A4
(fr)
|
2015-12-14 |
2019-06-12 |
David K. Thomas |
Compositions et procédés de traitement des dysfonctionnements cardiaques
|
CN107151255A
(zh)
*
|
2016-03-06 |
2017-09-12 |
复旦大学 |
硼酸类化合物及其制备方法和用途
|
CN107151254A
(zh)
*
|
2016-03-06 |
2017-09-12 |
复旦大学 |
一种作为20s蛋白酶体抑制剂的硼酸类化合物及其制备方法
|
MA45479A
(fr)
|
2016-04-14 |
2019-02-20 |
Janssen Biotech Inc |
Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen
|
US11447506B2
(en)
|
2016-05-09 |
2022-09-20 |
Anacor Pharmaceuticals, Inc. |
Crystal forms of crisaborole in free form and preparation method and use thereof
|
CN106008572B
(zh)
*
|
2016-05-23 |
2018-08-17 |
成都千禧莱医药科技有限公司 |
一类二肽硼酸化合物及制备方法和用途
|
EP3472151A4
(fr)
|
2016-06-21 |
2020-03-04 |
Orion Ophthalmology LLC |
Dérivés de prolinamide carbocycliques
|
JP7179721B2
(ja)
|
2016-06-21 |
2022-11-29 |
オリオン・オフサルモロジー・エルエルシー |
複素環式プロリンアミド誘導体
|
JP6681284B2
(ja)
*
|
2016-06-23 |
2020-04-15 |
信越化学工業株式会社 |
糖アルコール化合物の金属低減方法
|
JP6223508B2
(ja)
*
|
2016-06-27 |
2017-11-01 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
プロテアソーム阻害剤
|
WO2018038687A1
(fr)
|
2016-08-22 |
2018-03-01 |
Mustafa Nevzat Ilaç Sanayii A.Ş. |
Formulations pharmaceutiques comprenant un complexe bortézomib-cyclodextrine
|
WO2018060833A1
(fr)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Schéma posologique pour l'alpelisib, un inhibiteur de la phosphatidylinositol 3-kinase spécifique de l'isoforme alpha
|
CA3040820A1
(fr)
|
2016-10-20 |
2018-04-26 |
Pfizer Inc. |
Particules therapeutiques avec des composes peptidiques d'acide boronique ou d'ester de boronate et leurs procedes de fabrication et d'utilisation
|
US11584733B2
(en)
|
2017-01-09 |
2023-02-21 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
US11034667B2
(en)
|
2017-01-09 |
2021-06-15 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
CN110312727A
(zh)
|
2017-02-17 |
2019-10-08 |
费森尤斯卡比肿瘤学有限公司 |
一种改进的制备硼酸酯的方法
|
CA3054572A1
(fr)
|
2017-02-28 |
2018-09-07 |
Mayo Foundation For Medical Education And Research |
Composes et methodes de traitement du cancer
|
EP3672586A1
(fr)
|
2017-08-23 |
2020-07-01 |
Kezar Life Sciences |
Inhibiteurs d'immunoprotéasome et agent immunosuppresseur dans le traitement de troubles auto-immuns
|
JP2020533382A
(ja)
|
2017-09-14 |
2020-11-19 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
癌の組合せ治療
|
JP2018024694A
(ja)
*
|
2017-10-03 |
2018-02-15 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
プロテアソーム阻害剤
|
CN111491938B
(zh)
|
2017-11-16 |
2024-05-24 |
普林斯匹亚生物制药公司 |
免疫蛋白酶体抑制剂
|
DK3710457T3
(da)
*
|
2017-11-16 |
2022-10-24 |
Principia Biopharma Inc |
Immunproteasomhæmmere
|
US10537585B2
(en)
|
2017-12-18 |
2020-01-21 |
Dexcel Pharma Technologies Ltd. |
Compositions comprising dexamethasone
|
CN112004537A
(zh)
|
2018-01-09 |
2020-11-27 |
穿梭药业公司 |
用于治疗人疾病的选择性组蛋白去乙酰化酶抑制剂
|
US20210106522A1
(en)
|
2018-01-29 |
2021-04-15 |
Cognos Therapeutics, Inc. |
Intratumoral delivery of bortezomib
|
WO2019178438A1
(fr)
|
2018-03-15 |
2019-09-19 |
Abbvie Inc. |
Abbv-621 en combinaison avec des agents anticancéreux pour le traitement du cancer
|
US11243207B2
(en)
|
2018-03-29 |
2022-02-08 |
Mayo Foundation For Medical Education And Research |
Assessing and treating cancer
|
EP3873214A4
(fr)
|
2018-10-29 |
2022-07-13 |
Forma Therapeutics, Inc. |
Formes solides de (4-(2-fluoro-4-(1-méthyl-1h-benzo[d]imidazol-5-yl)benzoyl)pipérazin-1-yl)(1-hydroxycyclopropyl)méthanone
|
CN109824756B
(zh)
*
|
2019-03-19 |
2022-03-22 |
山东大学 |
含有4-(苯磺酰基)哌嗪-2-酮的苯丙氨酸衍生物及其制备方法与应用
|
CN114437119A
(zh)
*
|
2020-10-30 |
2022-05-06 |
苏州开拓药业股份有限公司 |
一种c-Myc蛋白抑制剂及其制备方法和用途
|
JP2023553011A
(ja)
*
|
2020-12-02 |
2023-12-20 |
ホフマン・テクノロジーズ・エルエルシー |
非ヒト哺乳動物においてがんを調節するための組成物および方法
|
TW202237143A
(zh)
*
|
2020-12-10 |
2022-10-01 |
南韓商Lg化學股份有限公司 |
酸(Boronic Acid)化合物
|
US11964993B2
(en)
|
2021-07-03 |
2024-04-23 |
Shilpa Pharma Lifesciences Limited |
Crystalline bortezomib process
|
EP4134083A1
(fr)
|
2021-08-12 |
2023-02-15 |
Extrovis AG |
Compositions pharmaceutiques de bortézomib
|
CN113957441B
(zh)
*
|
2021-10-29 |
2024-01-02 |
光华科学技术研究院(广东)有限公司 |
蚀刻液及其制备方法和应用
|
WO2023220655A1
(fr)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Méthodes pour surmonter la résistance aux médicaments par ré-sensibilisation de cellules cancéreuses à un traitement avec une thérapie antérieure par l'intermédiaire d'un traitement avec une thérapie par lymphocytes t
|
WO2023220641A2
(fr)
|
2022-05-11 |
2023-11-16 |
Juno Therapeutics, Inc. |
Méthodes et utilisations associées à une thérapie par lymphocytes t et leur production
|
WO2024097905A1
(fr)
|
2022-11-02 |
2024-05-10 |
Celgene Corporation |
Méthodes de traitement au moyen d'une thérapie par lymphocytes t et d'une thérapie d'entretien par agent immunomodulateur
|